However, as most cases of DOA are caused by OPA1 variants, efforts to develop gene therapies have focused on targeting the haploinsufficiency and dominant-negative mechanisms contributing to RGC loss. The gene discussed is OPA1; the disease is autosomal dominant optic atrophy.